Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cancer Discovery

Topics

Biology

Cancer Oncology

Medicine

Internal Medicine

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1158/2159-8290.cd-18-1022